Navigation Links
Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
Date:12/3/2010

DALLAS and NEW YORK, Dec. 3, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.  

The video can be found under the Testimonial section of the MuGard website (www.MuGard.com), or by clicking on the following link: www.MuGard.com/testimonials/.

"We continue receiving many anecdotal feedback and testimonials from patients, doctors, and nurses," said Frank Jacobucci, VP of Sales and Marketing, Access Pharmaceuticals.  He continued, "We are gratified at the overwhelmingly positive reception MuGard is receiving in the oncology community and we plan to continue updating the site with additional testimonials that demonstrate the significant clinical benefit experienced using MuGard in both a prophylactic and treatment setting."

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Consolidated Portland, Maine Healthcare Market Will Hamper Pharmaceutical Reps Access to Physicians
2. Consortium on Intraosseous (IO) Vascular Access Recommends IO Access for Emergent and Nonemergent Situations
3. Reportlinker Adds Global HPLC Systems & Accessories Industry
4. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
5. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
6. Access Pharmaceuticals to Present at LifeTech Capital Miami Medical Investors Conference on November 12th
7. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
8. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
9. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
10. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
11. Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral™ Formulation of Widely-Marketed Injectable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
(Date:6/7/2017)... June 7, 2017  Novavax, Inc., (Nasdaq: NVAX ... Phase 2 trials of its RSV F protein recombinant nanoparticle ... age have been published in the journal Vaccine ... shared in prior scientific conferences). The Company previously announced ... Novavax is developing the RSV F Vaccine with the goal ...
(Date:6/5/2017)... June 5, 2017 Kohll,s Pharmacy & Homecare is the ... the United States . The Raizer is a simple ... person up to an almost-standing position within a ... by one assistant and does not require any ... that a child can operate it, and lightweight ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... ... personal financial planning to families and business owners in North Central West Virginia, ... help provide services to differently abled residents in the region. , The Stepping ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... grant from the American Heart Association (AHA) to launch a Rheumatic Heart Disease ... the prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged ...
(Date:6/22/2017)... ... June 22, 2017 , ... Vighter, a premier provider ... certification for ANSI/ASIS PSC.1-2012. The company’s work in countries throughout Southwest Asia, South ... law has been degraded. The PSC.1 standard was created to protect fundamental freedoms ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, a premier ... private equity firm, has invested $3.35 million in the company. , “We ... Capital offers the smart money, speed to market and accountability we had been ...
Breaking Medicine News(10 mins):